Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1% of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA.

Original languageEnglish (US)
Pages (from-to)335-344
Number of pages10
JournalPatient Preference and Adherence
Volume3
DOIs
StatePublished - Nov 17 2009
Externally publishedYes

Fingerprint

Biological Therapy
Patient Preference
Patient Satisfaction
Rheumatoid Arthritis
medication
Medication Adherence
Patient Compliance
Biological Products
Decision Making
quality of life
Chronic Disease
Therapeutics
Quality of Life
Disease
decision making
Population

Keywords

  • Adherence
  • Biologics
  • Patient preference
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{61b19fd7257149978fd37930f12ac969,
title = "Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy",
abstract = "Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1{\%} of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA.",
keywords = "Adherence, Biologics, Patient preference, Rheumatoid arthritis",
author = "Jennifer Barton",
year = "2009",
month = "11",
day = "17",
doi = "10.2147/PPA.S5835",
language = "English (US)",
volume = "3",
pages = "335--344",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

AU - Barton, Jennifer

PY - 2009/11/17

Y1 - 2009/11/17

N2 - Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1% of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA.

AB - Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1% of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA.

KW - Adherence

KW - Biologics

KW - Patient preference

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=78049288337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049288337&partnerID=8YFLogxK

U2 - 10.2147/PPA.S5835

DO - 10.2147/PPA.S5835

M3 - Article

VL - 3

SP - 335

EP - 344

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -